Related Experiment Video
Updated: Nov 5, 2025

10:38
Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases
Published on: December 22, 2023
760
Alzheimer mutant speeds APP transport
Sam Gandy1,2,3, Michelle E Ehrlich4,5,6
1Department of Neurology and The Mount Sinai Center for Cognitive Health and NFL Neurological Care, Icahn School of Medicine at Mount Sinai, New York, NY.
The Journal of Experimental Medicine
|May 14, 2021
Summary
A rare Alzheimer's disease mutation, APPS198P, causes increased amyloid-beta (Aβ) accumulation. This occurs due to accelerated protein folding and processing, leading to enhanced Aβ generation in the brain.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Rare familial forms of Alzheimer's disease (AD) are linked to mutations in the amyloid precursor protein (APP).
- Most known APP mutations are located in exons 16 or 17, but the APPS198P mutation is in exon 5.
Purpose of the Study:
- To investigate the impact of the APPS198P mutation on amyloid-beta (Aβ) production.
- To elucidate the cellular mechanisms underlying Aβ generation in APPS198P.
Main Methods:
- Generation of APPS198P transgenic mice.
- Analysis of Aβ levels in mouse brains.
- Cellular studies using cultured cells expressing APPS198P.
Main Results:
- APPS198P transgenic mice exhibit elevated levels of Aβ in their brains.
- In cultured cells, APPS198P undergoes rapid endoplasmic reticulum (ER) folding.
- This accelerated folding leads to premature transport to late endosomal/lysosomal compartments, enhancing Aβ generation.
Conclusions:
- The APPS198P mutation promotes Aβ accumulation through accelerated protein processing and enhanced Aβ production.
- This finding provides new insights into the molecular mechanisms of rare familial Alzheimer's disease.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
958
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
958
Alzheimer's Disease: Treatment
467
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
467
Dementia
268
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
268

